BTMD · biote Corp.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Biote reported Q2 revenue down 9.5% to $44.2M and cut full-year guidance to above $175M (from above $190M) and adjusted EBITDA above $25M (from above $38M), citing recall-driven procedure revenue declines, while highlighting resolved supply, normalized Asteria Health production, and expected sequential procedure improvement in 2H.
- + Q2 cash balance rebuilt to $11.2M from $5.3M at March 31, 2026.
- + Management expects sequential procedure revenue improvement in both Q3 and Q4 2026.
- + Legal expense expected to decline after recent resolution of outstanding legal matters.
- − Full-year 2026 adjusted EBITDA guidance cut to above $25M from above $38M.
- − Gross margin compressed to 65.4% from 71.6% due to recall-related costs.
- − Q2 swung to net loss of $7.4M (diluted LPS of $0.23) vs. net income of $3.9M ($0.10 EPS) a year ago.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BTMD
this stock
biote Corp.
|
$48.86M | -49.0% | -2.5% | 13.6 | 3.9% |
|
HCA
HCA Healthcare, Inc.
|
$95.18B | -8.8% | +7.1% | 14.8 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.85B | -8.7% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.10B | +31.3% | +0.9% | 10.1 | 2.3% |
|
EHC
Encompass Health Corp
|
$12.17B | +14.5% | +10.5% | 20.1 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BTMD | -5.4% | -17.7% | +1.9% | -19.2% | -49.0% |
| SPY | +1.7% | +1.0% | +22.4% | +0.8% | +13.4% |
| vs SPY | -7.0% | -18.7% | -20.5% | -20.1% | -62.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.